Use of PrEP for HIV Prevention Among At-Risk Teens in US

JAMA Pediatrics

EMBARGOED FOR RELEASE: 11 A.M. (ET), MONDAY, MAY 11, 2020

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamapediatrics/fullarticle/10.1001/jamapediatrics.2020.0824?guestAccessKey=b1250b3c-5ac8-43f1-9314-147864ee71a9&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=051120

 

What The Study Did: Nearly 60 articles were reviewed to assess the rate of preexposure prophylaxis (PrEP) use for HIV prevention among at-risk teens in the United States and to provide recommendations for how to improve access to and use of PrEP.

Authors: Allison L. Agwu, M.D., Sc.M., of the Johns Hopkins University School of Medicine in Baltimore, is the corresponding author.

 

(doi:10.1001/jamapediatrics.2020.0824)

Editor’s Note: The article includes conflict of interest disclosures. Please see the article for additional information, including other authors, author contributions and affiliations, conflicts of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.